Drug Trial Radar · NCT07463846
A Study to Evaluate ALN-2232 in Participants With Obesity
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Apr 28, 2027
Study completion Apr 28, 2028
Sponsor
- Lead sponsor
- Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
- Sponsor type
- Industry
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
Conditions
- Obesity
Interventions
ALN-2232Drug
ALN-2232 will be administered subcutaneously (SC)
PlaceboDrug
Placebo will be administered SC
TirzepatideDrug
Tirzepatide will be administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Frequency of Adverse Events (AEs)Time frame: Up to 12 months
- Part B: Percent Change from Baseline in Body WeightTime frame: Baseline up to Month 6
- Part C: Percent Change from Baseline in Body WeightTime frame: Baseline up to Month 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Mount Royal, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.